Valuation: COMPASS Pathways plc

Market Cap 1.6B 1.43B 1.32B 1.2B 2.24B 152B 2.28B 15.74B 6.32B 80.02B 6.01B 5.88B 252B P/E 2026 *
-5.38x
P/E 2027 * -6.9x
Enterprise Value 1.24B 1.11B 1.02B 928M 1.73B 118B 1.77B 12.21B 4.9B 62.09B 4.67B 4.57B 196B EV / Sales 2026 *
-
EV / Sales 2027 * 29.5x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-5.09%
1 week+3.49%
1 month-6.99%
3 months+1.94%
6 months+27.70%
Current year+67.68%
1 week 10.94
Extreme 10.94
12.5
1 month 10.72
Extreme 10.72
12.5
Current year 4.88
Extreme 4.88
15.87
1 year 4.88
Extreme 4.88
15.87
3 years 2.25
Extreme 2.25
15.87
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 01/08/2022
Director of Finance/CFO 54 01/03/2024
Chief Tech/Sci/R&D Officer 66 01/05/2024
Director TitleAgeSince
Chairman 74 29/03/2024
Director/Board Member 69 01/04/2020
Director/Board Member 67 01/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Tax

Chief Executive Officer

-5,962 0.0062%
27/5/26 Free

Director

21,110 0.0220%
27/5/26 Free

Director

21,110 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
-5.09%+3.49%+83.07%+101.92% 1.6B
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.20%+7.13%+51.13%+185.68% 39.59B
Weighted average by Cap. +0.16%+5.44%+48.13%+176.37%

Financials

2026 *2027 *
Net sales - 39.7M 35.55M 32.7M 29.63M 55.39M 3.77B 56.43M 390M 157M 1.98B 149M 146M 6.25B
Net income -299M -267M -246M -223M -417M -28.35B -424M -2.93B -1.18B -14.91B -1.12B -1.1B -47.03B -252M -226M -208M -188M -351M -23.92B -358M -2.47B -993M -12.58B -945M -925M -39.68B
Net Debt -359M -322M -296M -268M -501M -34.09B -510M -3.53B -1.42B -17.93B -1.35B -1.32B -56.55B -432M -387M -356M -323M -603M -41.03B -614M -4.25B -1.7B -21.58B -1.62B -1.59B -68.07B
Projected Income Statement - Annual - COMPASS Pathways plc
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
30/10/26 US$11.57 -5.09% 2,180,332
29/10/26 US$12.19 -0.73% 1,382,317
28/10/26 US$12.28 +3.98% 1,421,025
27/10/26 US$11.81 +6.88% 2,275,222
26/10/26 US$11.05 -1.16% 1,520,359
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - COMPASS Pathways plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
11.57USD
Average target price
23.75USD
Spread / Average Target
+105.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - COMPASS Pathways plc
  1. Stock Market
  2. Stocks
  3. CMPS Stock